178 related articles for article (PubMed ID: 35196526)
21. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
Rankin EB; Tomaszewski JE; Haase VH
Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
[TBL] [Abstract][Full Text] [Related]
22. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
23. [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
Zhou J; Li NY; Zhou XJ; Zhou HB; Wu B; Jiang SJ; Ma HH; Zhang RS
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):145-50. PubMed ID: 20450758
[TBL] [Abstract][Full Text] [Related]
24. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
25. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T
J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800
[TBL] [Abstract][Full Text] [Related]
26. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
Huang YR; Zhang J; Wang JD; Fan XD
Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
[TBL] [Abstract][Full Text] [Related]
27. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
28. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
29. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
[TBL] [Abstract][Full Text] [Related]
30. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
31. De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.
Ding X; Zhang C; Frerich JM; Germanwala A; Yang C; Lonser RR; Mao Y; Zhuang Z; Zhang M
J Neurosurg; 2014 Aug; 121(2):384-386. PubMed ID: 24678776
[TBL] [Abstract][Full Text] [Related]
32. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study.
Favier J; Meatchi T; Robidel E; Badoual C; Sibony M; Nguyen AT; Gimenez-Roqueplo AP; Burnichon N
Mod Pathol; 2020 Jan; 33(1):57-64. PubMed ID: 31383958
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
[TBL] [Abstract][Full Text] [Related]
34. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
35. VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma.
von Teichman A; Compérat E; Behnke S; Storz M; Moch H; Schraml P
Mod Pathol; 2011 Apr; 24(4):571-8. PubMed ID: 21151099
[TBL] [Abstract][Full Text] [Related]
36. Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-α binding site in VHL protein.
Liu SJ; Wang JY; Peng SH; Li T; Ning XH; Hong BA; Liu JY; Wu PJ; Zhou BW; Zhou JC; Qi NN; Peng X; Zhang JF; Ma KF; Cai L; Gong K
Genet Med; 2018 Oct; 20(10):1266-1273. PubMed ID: 29595810
[TBL] [Abstract][Full Text] [Related]
37. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma.
North PE; Mizeracki A; Mihm MC; Mrak RE
Clin Neuropathol; 2000; 19(3):131-7. PubMed ID: 14606586
[TBL] [Abstract][Full Text] [Related]
38. [Gastroenterological manifestations of von Hippel-Lindau disease].
Koniusz J; Dąbkowski K; Buczek K; Gomółka A; Starzyńska T
Pol Merkur Lekarski; 2017 Aug; 43(254):53-55. PubMed ID: 28875969
[TBL] [Abstract][Full Text] [Related]
39. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease.
Laks S; van Leeuwaarde R; Patel D; Keutgen XM; Hammel P; Nilubol N; Links TP; Halfdanarson TR; Daniels AB; Tirosh A;
Cancer; 2022 Feb; 128(3):435-446. PubMed ID: 34735022
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.
Liang X; Shen D; Huang Y; Yin C; Bojanowski CM; Zhuang Z; Chan CC
Ophthalmology; 2007 Jan; 114(1):147-56. PubMed ID: 17070589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
